Part B Insider - 2006 Issue 26
Oncologists: Prevent Steep Cuts To Oncology Drugs: Make Your Voice Heard
Subscribe or sign in to view the full article.
Article Overview
This article summarizes an HHS Office of Inspector General survey about oncology drug pricing and the possibility of Medicare payment cuts. It is aimed at oncology practices, coders, and reimbursement professionals who need to understand why the issue matters, which drug payments are being scrutinized, and the general policy context behind the coverage.
Why This Topic Matters
The article matters because it highlights a Medicare payment review that could affect oncology drug reimbursement and practice revenue. It also places the issue in the context of federal oversight and pricing methodology concerns.
What You Will Learn
- The general purpose of the HHS OIG survey discussed in the article
- Why oncology drug pricing is under Medicare review
- How CMS and the OIG are positioned on possible payment reductions
- The broader reimbursement implications for oncology practices
Who Should Read This
- Oncology practices
- Medical coders
- Billing staff
- Reimbursement specialists
- Practice administrators
Codes Discussed
Subscribe or sign in to view the full article.
Quick, Current, Complete - www.findacode.com